TEVA PHARMACEUTICAL INDUSTRIES LIMITED, TEL AVIV, L3
Annual Report to Security Holders
Innovative Portfolio and Consistent Execution of Pivot to Growth Strategy Deliver Third Consecutive Year of Growth; Pipeline Positioned to Unlock Significant Value Potential
To Present at the 44th Annual J.P. Morgan Healthcare Conference: Pivot to Growth Strategy Delivering Growth and Transforming through Innovation
Teva Extends Maturity Date of Revolving Credit Agreement to 2028
Innovative Portfolio Drives 11th Consecutive Quarter of Growth in Q3 2025; Increases 2025 Outlook for Austedo® and Non-GAAP EPS
Teva's Q2 2025 Growth Fueled by Innovative Portfolio, Ups 2025 Revenue Outlook
Shareholder votes
News, Securities Holder Rights or Indentures, Description of Registrant's Securities, Legal Opinion
FY 2024
Q3
Q2
Q1
Prospectus filed pursuant to Rule 424(b)(5)
S-3ASR
Prospectus filed pursuant to Rule 424(b)(3)
Definitive Proxy Statement
Additional Proxy Materials
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Specialized Disclosure Report
Free Writing Prospectus
Submission Upload
Correspondence